The study of mRNA-4359 in participants with advanced solid tumors
ModernaTX, Inc started a new clinical trial of Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors.
The company ModernaTX, Inc is enrolling patients into the clinical trial investigating Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors.
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
The study start date is August 18, 2022.
Among the inclusion criteria are:
- Dose Escalation (Arm 1a): Participant has histologically confirmed locally advanced or metastatic cancer (cutaneous melanoma, non-small-cell lung carcinoma (NSCLC), non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, Microsatellite stable colorectal cancer (MSS CRC), basal cell carcinoma, or triple negative breast cancer) with measurable disease as determined by RECIST v1.1. Arm 1a participants must have received, and then progressed, relapsed, or been intolerant to, or ineligible for, at least 1 standard treatment regimen in the advanced or metastatic setting.
- The trial is designed to enroll male and female 18 Years and older and is being conducted in several investigational sites in the United States.
This page provides a more detailed overview of the inclusion/exclusion criteria, contact information, and further details of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05533697.
